Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 9/2023

Open Access 06-07-2023 | Brain Tumor

Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors

Authors: Ryan R. Woods, MD, Glenn J. Lesser, MD

Published in: Current Treatment Options in Oncology | Issue 9/2023

Login to get access

Opinion statement

Patients with primary brain tumors are at a substantially elevated risk of venous thromboembolism (VTE) compared to other disease states or other forms of malignancy. Deep venous thrombosis (DVT) and pulmonary embolism (PE), often complicate the care of patients with primary brain tumors, and treatment may pose specific unique risks and considerations for management. This paper critically reviews the relevant literature and the most common treatment options in addition to a discussion regarding the relative risk considerations for neurooncology patients facing thromboembolic disease.
Literature
1.
2.
Jeraq M, et al. Venous thromboembolism in brain tumor patients. Adv Exp Med Biol. 2017;906:215–28.CrossRefPubMed
3.
Mir SeyedNazari P, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thrombo Haemost: JTH. 2018;16(6):1121–7.CrossRef
4.
Agnelli G, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.CrossRefPubMed
5.
Landman GW, Gans ROB. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2011;364(12):1178.CrossRefPubMed
6.
Goldhaber SZ, et al. Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II. Thromb Haemost. 2017;117(11):2045–52.CrossRefPubMed
7.
Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9-16.PubMed
8.
Bĕlohlávek J, et al. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013;18(2):129–38.PubMedPubMedCentral
9.
Palareti G, et al. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost. 2010;104(5):1063–70.PubMed
10.
Robert-Ebadi H, Righini M. Should we diagnose and treat distal deep vein thrombosis?. Hematol Am Soc Hematol Educ Program. 2017;2017(1):231–6.CrossRef
11.
Pinede L, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103(20):2453–60.CrossRefPubMed
12.
Kearon C, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901–7.CrossRefPubMed
13.
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–738.CrossRefPubMedPubMedCentral
14.
Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016;68(23):2508–21.CrossRefPubMed
15.
Khoury MN, et al. Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. Neuro-Oncol Pract. 2016;3(2):87–96.CrossRef
16.
Li Yao, et al. Risk factors for the incidence of apoplexy in pituitary adenoma: a single-center study from southwestern China. Chin Neurosurg J. 2020;6:20.CrossRefPubMedPubMedCentral
17.
Chinot OL, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4):334–40.CrossRefPubMed
18.
19.
Lee AYY, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53.CrossRefPubMed
20.
Deitcher SR, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389–96.CrossRefPubMed
21.
Lee AYY, et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer. 2013;13:284.CrossRefPubMedPubMedCentral
22.
Mantia C, et al. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017;129(25):3379–85.CrossRefPubMed
23.
Chai-Adisaksopha C, et al. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thromb Haemost. 2017;117(3):589–94.CrossRefPubMed
24.
Yust-Katz S, et al. Venous thromboembolism (VTE) and glioblastoma. J Neuro-Oncol. 2015;124(1):87–94.CrossRef
25.
EINSTEIN–PE Investigators, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.CrossRef
26.
Prins MH, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21.CrossRefPubMedPubMedCentral
27.
28.
• Raskob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24. (The Hokusai VTE Cancer Trial was an important prospective trial establishing the safety of DOAC’s in cancer patients exclusively.)CrossRefPubMed
29.
Goldhaber SZ, Schellong S, Kakkar A, Eriksson H, Feuring M, Kreuzer J, Fraessdorf M, Schulman S. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost. 2016;116(4):714–21.PubMed
30.
Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost: JTH. 2019;17(1):72–6.CrossRefPubMed
31.
Young AM, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23.CrossRefPubMed
32.
McBane RD 2nd, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost: JTH. 2020;18(2):411–21.CrossRefPubMed
33.
•• Agnelli G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–607. (The CARAVAGGIO study represents a recent review of a DOAC in cancer patients.)CrossRefPubMed
34.
Streiff MB, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, Version 2.2018. J Natl Compr Cancer Netw: JNCCN. 2018;16(11):1289–303.CrossRefPubMed
35.
36.
Weitz JI, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–22.CrossRefPubMed
37.
Agnelli G, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.CrossRefPubMed
Metadata
Title
Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors
Authors
Ryan R. Woods, MD
Glenn J. Lesser, MD
Publication date
06-07-2023

Other articles of this Issue 9/2023

Current Treatment Options in Oncology 9/2023 Go to the issue

ReviewPaper

Enhanced Photodynamic Therapy by Improved Light Energy Capture Efficiency of Porphyrin Photosensitizers

ReviewPaper

CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?

ReviewPaper

Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials

ReviewPaper

Treatment of recurrent or metastatic nasopharyngeal carcinoma

ReviewPaper

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

ReviewPaper

Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits